MedPath

ASTON Sci. Inc.

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:1
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (75.0%)
Phase 1
1 (25.0%)

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

Phase 2
Not yet recruiting
Conditions
Advanced Ovarian Cancer
Interventions
Biological: AST-201
Drug: Placebo
Drug: rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)
First Posted Date
2023-04-03
Last Posted Date
2023-07-20
Lead Sponsor
Aston Sci. Inc.
Target Recruit Count
98
Registration Number
NCT05794659
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

Phase 2
Recruiting
Conditions
Gastric Cancer
Interventions
First Posted Date
2023-03-16
Last Posted Date
2024-07-10
Lead Sponsor
Aston Sci. Inc.
Target Recruit Count
24
Registration Number
NCT05771584
Locations
🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

🇨🇳

China Medical University Hospital, Taichung, Taiwan

🇨🇳

Taichung Veterans General Hospital, Taichung, Taiwan

and more 3 locations

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
Biological: AST-301(pNGVL3-hICD)
Drug: Placebo
First Posted Date
2021-12-20
Last Posted Date
2024-06-17
Lead Sponsor
Aston Sci. Inc.
Target Recruit Count
10
Registration Number
NCT05163223
Locations
🇺🇸

Ironwood Cancer and Research Centers, Chandler, Arizona, United States

🇺🇸

Scripps Health, La Jolla, California, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 14 locations

AST-021p Study in Advanced Solid Tumors

Phase 1
Active, not recruiting
Conditions
Advanced Cancer
Interventions
First Posted Date
2021-04-28
Last Posted Date
2023-07-20
Lead Sponsor
Aston Sci. Inc.
Target Recruit Count
19
Registration Number
NCT04864418
Locations
🇰🇷

Korea University Anam Hospital, Seoul, Korea, Republic of

🇰🇷

Korea University Guro Hospital, Seoul, Korea, Republic of

🇰🇷

Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

News

No news found
© Copyright 2025. All Rights Reserved by MedPath